- Home
- VIVS vs SPRC Comparison
VIVS vs SPRC Comparison
Compare VIVS & SPRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- SPRC
- Stock Information
- Founded
- VIVS 2007
- SPRC 2004
- Country
- VIVS United States
- SPRC Israel
- Employees
- VIVS N/A
- SPRC N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- SPRC Biotechnology: Pharmaceutical Preparations
- Sector
- VIVS Health Care
- SPRC Health Care
- Exchange
- VIVS Nasdaq
- SPRC Nasdaq
- Market Cap
- VIVS 3.6M
- SPRC 3.4M
- IPO Year
- VIVS N/A
- SPRC N/A
- Fundamental
- Price
- VIVS $1.80
- SPRC $0.31
- Analyst Decision
- VIVS
- SPRC
- Analyst Count
- VIVS 0
- SPRC 0
- Target Price
- VIVS N/A
- SPRC N/A
- AVG Volume (30 Days)
- VIVS 137.3K
- SPRC 6.0M
- Earning Date
- VIVS 06-06-2025
- SPRC 02-15-2025
- Dividend Yield
- VIVS N/A
- SPRC N/A
- EPS Growth
- VIVS N/A
- SPRC N/A
- EPS
- VIVS N/A
- SPRC N/A
- Revenue
- VIVS $122,000.00
- SPRC $1,306,000.00
- Revenue This Year
- VIVS $59.08
- SPRC N/A
- Revenue Next Year
- VIVS $18.24
- SPRC N/A
- P/E Ratio
- VIVS N/A
- SPRC N/A
- Revenue Growth
- VIVS N/A
- SPRC N/A
- 52 Week Low
- VIVS $1.56
- SPRC $0.20
- 52 Week High
- VIVS $21.96
- SPRC $1.79
- Technical
- Relative Strength Index (RSI)
- VIVS N/A
- SPRC 50.56
- Support Level
- VIVS N/A
- SPRC $0.27
- Resistance Level
- VIVS N/A
- SPRC $0.32
- Average True Range (ATR)
- VIVS 0.00
- SPRC 0.03
- MACD
- VIVS 0.00
- SPRC -0.00
- Stochastic Oscillator
- VIVS 0.00
- SPRC 40.58
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
About SPRC SciSparc Ltd.
SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.